Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology Profile | FDA Health News
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Is Puma Biotechnology (PBYI) Stock a Solid Choice Right Now?
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha